James Alver
Urology · Riverview, FLNPI 1356337240
Payments from drug & device makers
Across 148 payments — averaging $402.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$44K
- Astellas Pharma US Inc$12K
- Johnson & Johnson$655
- Teleflex LLC$539
- Axonics, Inc.$335
- Boston Scientific$321
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$10,34017%
- Travel & lodging$8431%
- Food & beverage$4,5578%
- Education$1440%
- Other$43,61173%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 5 | $43,668 |
| Astellas Pharma US Inc | 31 | $12,244 |
| Johnson & Johnson | 24 | $655 |
| Teleflex LLC | 7 | $539 |
| Axonics, Inc. | 15 | $335 |
| Boston Scientific | 10 | $321 |
| Procept Biorobotics Corporation | 3 | $210 |
| Medtronic(2 entities) | 2 | $206 |
| Valencia Technologies Corporation | 2 | $182 |
| AbbVie | 9 | $135 |
| Bayer | 4 | $120 |
| Myriad Genetic Laboratories, Inc. | 2 | $119 |
| Pfizer | 4 | $94 |
| Dendreon Pharmaceuticals LLC | 2 | $69 |
| Angiodynamics, Inc. | 3 | $62 |
| Novartis | 3 | $62 |
| Palette Life Sciences, Inc. | 1 | $60 |
| Urogen Pharma, Inc. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Endo Pharmaceuticals Inc. | 2 | $45 |
| Immunitybio, Inc. | 1 | $38 |
| Myovant Sciences Inc. | 2 | $35 |
| Halozyme Inc | 2 | $35 |
| Acerus Pharmaceuticals Corporation | 1 | $24 |
| Metuchen Pharmaceuticals | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Calyxo, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Coloplast | 1 | $14 |
| Ambu Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISPOSABLE BIOPSY FORCEPS$43,397
- SINGLE USE BIOPSY VALVE (Sterile)$43,397
- Single Use Electrosurgical Snare SD-400$43,397
- Single Use Electrosurgical Hemostatic Forceps$43,397
- MYRBETRIQ$11,355
- Erleada$254
- Barrigel$190
- INTERSTIM$187
- AquaBeam Robotic System$149
- UroLift$139
- AKEEGA$133
- UroLift System$109
- Prolaris$103
- XTANDI$102
How this compares
$59,495 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 105 | $104,723 |
| GemtesaVibegron | 40 | $39,436 |
| Tamsulosin Hcl | 963 | $13,735 |
| Testosterone | 65 | $12,006 |
| Solifenacin Succinate | 152 | $9,956 |
| Dutasteride | 225 | $7,997 |
| Silodosin | 48 | $4,979 |
| Potassium Citrate ErPotassium Citrate | 50 | $4,333 |
| Methenamine Hippurate | 53 | $4,093 |
| Trospium Chloride | 53 | $3,915 |
| Vardenafil Hcl | 12 | $3,587 |
| Estradiol | 60 | $3,582 |
| Tadalafil | 45 | $2,389 |
| Finasteride | 194 | $2,197 |
| Trospium Chloride ErTrospium Chloride | 14 | $1,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $12,244 | $104,723105 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $52 | $39,43640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.
Other urology in Riverview
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
- Craig HermanPompano Beach$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.